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over the past 200 years, there have been countless groundbreaking discoveries in biology
and medicine at Yale university. however, one particularly noteworthy discovery with pro-
foundly important and broad consequences happened here in just the past two decades. in
2009, Thomas Steitz, the Sterling Professor of Molecular biophysics & biochemistry, was
awarded the Nobel Prize in chemistry for “studies of the structure and function of the ribo-
some,” along with Venkatraman Ramakrishnan of the MRc laboratory of Molecular biology
and Ada E. Yonath of the Weizmann institute of Science. This article covers the historical
context of Steitz’s important discovery, the techniques his laboratory used to study the ri-
bosome, and the impact that this research has had, and will have, on the future of biologi-
cal and medical research.
introduction
One of the fundamental tenets of biol-
ogy  is  the  relationship  between  DNA,
RNA,  and  protein.  The  central  dogma
states that DNA is transcribed into RNA,
and RNA is translated into protein. Tran-
scription  and  translation  occur  by  very
complex mechanisms that continue to be
subjects of intense study. It is now a well-
known fact that a protein’s structure and its
function are closely linked, and the genetic
instructions conveyed from DNA to RNA
provide specific instructions on how to syn-
thesize proteins with unique functions in-
side and outside the cell. However, none of
this was known in the 1930s, when scien-
tists first attempted to deduce the molecular
structures of proteins [1]. In fact, it was not
until the 1950s that scientists were first able
to determine the three-dimensional struc-
ture of a protein, myoglobin, on the molec-
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light is reflected by the skin of the apple into
the human retina. The brain then interprets
the information from the retina as the color
red. However, as we try to visualize objects
that are progressively smaller and smaller
with only visible light, we reach a physical
limit at about 1,000 nanometers, or 0.001
millimeters. This size is approximately the
wavelength of red visible light. Thus, even if
we had an infinitely powerful magnifying
glass, a red object 1,000 nm in size could not
be  seen  because  the  object  is  physically
smaller than the light waves, making it im-
possible for them to reflect off the object. 
Proteins are even smaller — most range
from 4 to 6 nm in diameter, or 200 times
smaller than the wavelength of red light. At
these sizes, even the short wavelengths used
in electron microscopy are insufficient. Fur-
thermore, much of the structural information
about proteins is derived from understand-
ing the molecular interactions of individual
amino acids. 
X-ray crystallography describes a set of
techniques that allows the visualization of
these  extremely  small  objects,  including
molecules and atoms, using wavelengths of
light on the scale of 1 angstrom, or 0.1 nm.
The form of electromagnetic light produced
at these wavelengths is called an X-ray. Un-
fortunately, X-rays cannot be focused in the
same way visible light can be by a magnify-
ing glass. Instead, researchers grow crystals
of the protein being studied using methods
that slowly increase the concentration of
precipitant in a protein solution until the pro-
tein becomes insoluble, at which point crys-
tals begin forming [3]. Like salt or sugar
crystals, protein crystals are arranged as lat-
tices containing many repeating units or-
ganized and oriented in a regular fashion. In
the case of protein crystals, each crystal con-
tains perhaps millions of identical protein
molecules in locked arrangement. Success-
fully grown protein crystals are soaked in
cryoprotectant and flash frozen in liquid ni-
trogen and then brought to an X-ray beam
facility such as a synchrotron [4].
When monochromatic X-ray beams are
fired at the protein crystals, the molecular
electron clouds scatter the X-rays, which
combine constructively and destructively to
form a detectable diffraction pattern. The
crystal is rotated through 180 degrees to col-
lect a full set of 180 diffraction patterns, or
reflections  [5].  This  set  of  reflections  is
unique to different proteins. One hurdle that
arises from the use of X-ray crystallography
is the phase problem. Each reflection has an
intensity and a phase angle, but only the in-
tensities of the reflections can be measured,
not their phases. In order to solve the struc-
ture of the protein, the lost phase informa-
tion must be recovered by another method,
such as molecular replacement or multiple
heavy atom isomorphous replacement.
Using both amplitude and phase informa-
tion, electron density maps can be calculated
and are used to solve the three-dimensional
molecular structure of the protein. With a high-
quality protein crystal, today’s structure reso-
lutions  can  be  higher  than  1  ￅ,  giving
information about protein structure on the level
of the side chains and torsion angles of indi-
vidual amino acids. This molecular informa-
tion  about  proteins  allows  researchers  to
understand the physical mechanisms by which
proteins perform their functions. Furthermore,
researchers can solve the structures of protein
molecules bound to substrates or inhibitors,
providing novel insight into how enzymes cat-
alyze reactions with their substrates, or how
drugs bind proteins to change their function.
solving the structure of the
ribosome
Thomas Steitz was introduced to pro-
tein crystallography in the 1960s as a grad-
uate student at Harvard University in the
laboratory  of  William  Lipscomb. At  the
time, Max Perutz had just won the 1962
Nobel Prize for solving the crystal structure
of human hemoglobin [6]. Steitz attended a
series of lectures by Perutz on the structure
of myoglobin and became fascinated, real-
izing that this new way of understanding
proteins would certainly be the future [7].
His first project was working on purifying
and obtaining the structure of bovine car-
boxypeptidase A, a digestive enzyme. By
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structure of carboxypeptidase A to a resolu-
tion of 2 ￅ, fine enough to reveal all the mo-
lecular and physical details of the molecule.
Steitz then spent three years working at the
MRC Laboratory of Molecular Biology in
Cambridge under David Blow, during which
time he helped solve the structure of chy-
motrypsin, another digestive enzyme [7]. In
the fall of 1970, Steitz moved to Yale. Be-
tween 1970 and 1995, his laboratory deter-
mined the structures of many more proteins
and their complexes, including yeast hexok-
inase, DNA polymerase I, and HIV reverse
transcriptase [8,9,10].
Starting in the mid-1990s, Steitz’s lab-
oratory decided to tackle the structure and
function of the ribosome. Unlike proteins
such as carboxypeptidase A and hexokinase,
which are composed of hundreds of amino
acids, the ribosome is a massive complex
consisting of dozens of smaller proteins cou-
pled with thousands of nucleotides of RNA.
Analyzing this astounding degree of com-
plexity proved a difficult task. Indeed, it re-
quired exponentially better computational
power and laboratory technology than was
available for most of the 20th century. How-
ever, in the 40 years between the discovery
of the structure of hemoglobin and that of ri-
bosome, computational power for analyzing
diffraction patterns had increased 8,000-fold
and the rate of X-ray data collection had in-
creased 105 fold, setting the stage for Steitz’s
laboratory to tackle the last piece of the cen-
tral dogma that was not yet structurally un-
derstood.
The ribosome is a massive protein and
RNA complex that carries out the translation
of the nucleotide code on messenger RNA
(mRNA†) into functional protein. Different
mRNAs code for different proteins necessary
to life. Eukaryotic organisms, which include
humans, have two ribosomal subunits, the
large 60S and small 40S, which combine to
form the functional 80S complex. In contrast,
prokaryotes such as bacteria have similar, but
smaller subunits — a large 50S and small
30S, which combine to form a 70S complex.
Because bacterial cells are easier to grow and
can be used to produce the relatively large
amounts of protein needed to grow crystals,
Steitz’s team of researchers, led by Nenad
Ban, chose to focus first on solving the struc-
ture of the prokaryotic 50S subunit, with the
goal of obtaining a crystal structure with a
high resolution of around 2 ￅ. 
The  Steitz  laboratory’s  first  break-
through was in 1998, when they first solved
a 9 ￅ resolution structure of the 50S subunit
of the prokaryotic ribosome using crystals
of protein purified from the extremophile ar-
chaeon Haloarcula marismortui [11]. The 9
ￅ map was a significant improvement over
an older 20 ￅ map, which had been created
by cryo-electron microscopy. To solve the
phase problem, the researchers had to use a
method  called  multiple  isomorphous  re-
placement. They created heavy-atom deriv-
atives of the ribosome using a heavy atom
cluster compound containing as many as 18
tungsten atoms and fired X-rays into the de-
rivative crystals [11]. The derivative crystal
data sets were then used to solve the phase
problem.  The  most  important  discovery
made with the 9 ￅ map was that it revealed
numerous features on the ribosome consis-
tent with double-helical RNA, providing ev-
idence agreeing with previous studies by the
scientific  community  showing  that  ribo-
somes were actually 60 percent RNA by
weight [11].
One year later, in 1999, further progress
was made toward a 2 ￅ resolution structure.
Steitz’s team reported in the journal Nature
that they had definitively placed protein and
RNA structures into a 5 ￅ resolution map.
The new structure revealed the positions of
major structural motifs on the ribosome, in-
cluding  the  polypeptide  exit  tunnel,  the
binding sites for elongation factors G and
Tu, and the sarcin-ricin loop [12]. These
three motifs are critical components of the
functional ribosome. The polypeptide exit
tunnel is the exit route for proteins being
synthesized in the ribosome, and obstruction
of  the  tunnel  can  stop  protein  synthesis.
Elongation factors G and Tu are required for
polypeptide synthesis and are secured to the
ribosome by the binding sites. Finally, the
sarcin-ricin loop is the target of the castor
bean protein ricin, and its modification by
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the future, a compound could be developed
to block ricin’s activity and prevent ricin
toxicity.
In  2000,  Steitz’s  laboratory  finally
reached the goal of obtaining a high-resolu-
tion structure, publishing a 2.4 ￅ resolution
map in the journal Science. At this resolu-
tion, the researchers were able to definitively
place nearly all of the 50S subunit’s 3,045
nucleotides and 31 proteins. This high-reso-
lution structure revealed the stabilizing role
of the ribosomal proteins in the ribosomal
complex and allowed researchers to begin
looking at the molecular interactions be-
tween  different  side  chains  [14].  It  also
opened the way for discovering the molecu-
lar  mechanisms  of  many  antibiotics.  By
solving the crystal structure of the 50S sub-
unit in complex with antibiotics that inhibit
ribosomal translation, researchers can better
understand the molecular interactions, in-
cluding hydrophobic interactions, hydrogen
bonds, and covalent bonds that form upon
antibiotic binding, and how those binding
interactions affect ribosomal activity.
Steitz continues to study the molecular
mechanisms of antibiotic actions to this day.
For example, in 2002, the laboratory de-
scribed how four different macrolide antibi-
otics,  including  azithromycin  and
erythromycin,  bind  the  50S  subunit.
Macrolide antibiotics were found to exert
their effects by binding in the polypeptide
exit tunnel of the 50S subunit, inhibiting
translation [15]. In 2005, Steitz’s group de-
scribed a single-nucleotide mutation in H.
marismortui that conferred macrolide an-
tibiotic resistance [16]. And in 2008, a pub-
lication in the Journal of Molecular Biology
described eleven mutations in in H. maris-
mortui ribosome that could render it resist-
ant to the antibiotic anisomycin [17].
Such structural studies reveal the mech-
anisms by which antibiotic resistance can
develop. They also provide the groundwork
for rational drug design — the synthesis of
novel antibiotics that may fit in structurally
important grooves and rides on the protein.
In 2001, Steitz and others founded Rib-X
Pharmaceuticals, a company devoted to de-
veloping novel broad-spectrum antibiotics.
By incorporating a structural understanding
of how current antibiotics interact with ri-
bosomes, Rib-X Pharmaceuticals hopes to
develop  antibiotics  that  can  overcome
known mechanisms of bacterial resistance.
Two such drugs currently in development
are delafloxacin, a fluoroquinolone that is
effective  against  Methicillin-resistant
Staphylococcus aureus (MRSA), and rade-
zolid, a novel oxazolidinone compound with
broad activity against Gram-positive bacte-
ria such as vancomycin-resistant Enterococ-
cus (VRE) [18]. This work is critical to the
battle  against  constantly  evolving
pathogens, many of which can develop re-
sistance that makes previous-generation an-
tibiotics no longer effective. 
conclusion
Since the 1950s, the structures of thou-
sands of proteins have been solved by X-ray
crystallography, but Thomas Steitz’s work
on the structure and function of the ribosome
allowed the scientific community to under-
stand a fundamental component of transla-
tion.  His  work  continues  to  have  broad
consequences in biology and medicine, es-
pecially in the battle against antibiotic-re-
sistant bacteria such as MRSA and VRE.
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